IMMUDYNE INC (IMMD) research, news, and more from GeoInvesting

Company description

Wed, 01 May 2013 04:00:00 GMT

Immudyne, Inc. engages in the manufacture, distribution, and sale of natural yeast beta glucan products for immune system support principally in the United States. It offers natural immune support products (patented, patent pending, and trade secret protected) with oral and topical applications for human use, as well as other grades of product for use in pets/animals. The company was founded in 1987 and is based in Mount Kisco, New York.

Research

Fri, 08 Apr 2016 16:08:55 GMT

IMMD ($0.30) - On March 7, 2016 westated that long time speculative play IMMD announced preliminary 2015 sales and issued strong 2016 revenue guidance. Fiscal 2015 revenues expected to be up 73% to $1.225 million, compared to fiscal 2014 and issued guidance of $10 million in sales for 2016.

In an 8K filed yesterday after the close, IMMD entered into a joint venture with Inate Scientific. IMMD would take a 78% interest stake in Inate, in exchange for up to 9.5 million shares. The agreement is predicated on Inate helping IMMD earn $5 million in pre-tax income by 2018. We encourage you to read the full write up bybaystreet.ca which we believe offers a comprehensive review of the proposed deal.

Based on pro-forma fully diluted shares of 59.7 million, if IMMD is able to obtain the 5 million in pre-tax income, it would equate to $0.08 in EPS (not taxed).

Readers should note that One Equity Research, who prepared the baystreet.ca note has been compensated by IMMD.

Research

Mon, 07 Mar 2016 16:39:32 GMT

IMMD ($0.24) pre announced 2015 revenues and issues guidance for 2016.

Fiscal 2015 Revenues Expected To Be Up 73% to $1.225 Million, Compared to Fiscal 2014
Projecting $10 Million in Revenues for Fiscal 2016
Focused on Cost Management and Profitability in Fiscal 2016

Bullish commentary from management:

While we are expecting double-digit growth from sales of our strategic raw ingredients in fiscal 2016, our direct-to-consumer efforts are expected to drive total sales to $10 Million, or cumulative growth of over 800% year-over-year. In the first two months of 2016, through all segments of our businesses, we have generated more than $1.2 Million in revenue.

In December, 2015 through the end of February, 2016 we launched a beta test of our direct-to-consumer marketing Joint Venture and generated approximately $1,180,000 in revenue. Going forward, we believe we can materially lower our costs and improve return on our invested capital. We expect this direct-to-consumer segment of our business to be modestly cash flow positive for Q1 2016, and for cash flow to accelerate in Q2 and beyond.

“2015 was a growth year in terms of sales for ImmuDyne”, commented Mark McLaughlin, CEO of ImmuDyne, Inc., “However, 2016 will be an inflection point for us as we put our products in the hands of tens of thousands of customers and improve our offering with first-hand knowledge of why Global Beauty Company clients have been purchasing increasing amounts of our raw ingredients. We believe we have a superior product offering for skin care, and for applications in numerous other multi-billion dollar verticals. We will explore opportunities where we can leverage our understanding of unmet health and wellness needs that can be addressed by our effective and safe beta-glucan agent. Additionally, we are in discussions with other direct-to-consumer proprietary product lines outside of ImmuDyne’s core technology that, if negotiated successfully, would complement the existing JV product offering.”

Investors should note, we have been tracking the stock since 2013 and management had stated back in 2013 that they expected to revenue run rate to minimally top $10 million by the third quarter of 2014. It seems management has had aggressive goals before which it failed to reach, but we will continue to keep a close eye on the Company.

Comments & Business Outlook

Fri, 15 Aug 2014 04:00:00 GMT

MT. KISCO, N.Y., Aug. 14, 2014 (GLOBE NEWSWIRE) -- ImmuDyne, Inc. (OTCQB:IMMD) announced today that it has entered into a definitive agreement with the Sedona Institute For Age Management, LLC an affiliate of the Sedona Integrative Medical Clinic, LLC, www.sedonaclinic.com, to complete a clinical study on a new application of the company's patented beta glucan technology.

The study will focus on a medical syndrome, which according to a mounting tide of scientific research is having a debilitating effect on the health and vitality of a large segment of our aging population. It is expected that the study will prove that the Company's beta glucan technology can impact this syndrome by modulating the human body's innate immune system. As many as 80 million people in the U.S. and one billion worldwide are affected.

Under the terms of the agreement, ImmuDyne will pay for the beta glucan products to be administered in this study and the blood tests necessary to measure changes in certain biomarkers. The Sedona Integrative Medical Clinic will perform all testing drawing on their 2,000 patient base for participants in the study.

The Sedona Institute for Age Management will supervise the study, develop the application and assist the Company in marketing and establishing new distribution channels for both the application under study as well as existing applications. The Sedona Institute will be compensated with shares of the Company's restricted stock for developing the application and performing the clinical study. They will also earn commissions on sales originated by the Institute.

Eric Haggard, a principal in both the Sedona Clinic and Sedona Institute stated, "This could be a game changer for ImmuDyne. We expect this important study to prove that ImmuDyne's patented beta glucan products will provide significant relief to these people and open the Company to a major new revenue stream."

Joeseph V. DiTrolio, M.D., ImmuDyne's U.S. Chief Medical Officer pointed out, "Sedona Institute is an exceptional opportunity for ImmuDyne to gain market share and patient data documentation for maximum benefit to our clients."

Mark McLaughlin, ImmuDyne's CEO, added, "This is a shareholder friendly, performance based opportunity which gives ImmuDyne the platform to generate this new data, and revenues. Moreover, we are actively pursuing other potential opportunities through which to market our products and increase sales."

Comments & Business Outlook

Mon, 31 Mar 2014 04:00:00 GMT

FORM 10-K For the fiscal year ended December 31, 2013

Immudyne, Inc.

Statement of Operations

	Year Ended December 31
	2013			2012


Sales	$	808,363		$	673,778

Cost of sales		181,304			199,908

Gross Profit		627,059			473,870

Compensation and related expenses		(651,699	)		(321,263	)

Professional fees		(128,329	)		(253,407	)

General and administrative expenses		(393,439	)		(439,225	)

Operating (Loss)		(546,408	)		(540,025	)

Legal settlement proceeds		210,000			-

License Fee		50,000			25,000

Other income		4,331			55,547

Interest (expense)		(3,385	)		(3,371	)

Net (Loss) Before Taxes		(285,462	)		(462,849	)

Deferred income tax benefit		17,200			17,200

Net (Loss)	$	(268,262	)	$	(445,649	)

Basic and diluted (loss) per share	$	(0.01	)	$	(0.02	)

Average number of common shares outstanding		29,375,000			27,523,000

The accompanying notes are an integral part of these financial statements

Comments & Business Outlook

Thu, 14 Nov 2013 05:00:00 GMT

Immudyne, Inc.

Statement of Operations

(unaudited)

	Three Months Ended September 30				Nine Months Ended September 30
	2013		2012		2013		2012

Sales	$	94,676	$	152,115	$	647,837	$	558,218

Cost of sales		17,475		53,854		124,181		190,778

Gross Profit		77,201		98,261		523,656		367,440

Compensation and related expenses		(102,166)		(104,668)		(380,154)		(329,641)

Professional fees		(20,129)		(71,827)		(104,157)		(175,344)

General and administrative expenses		(123,572)		(85,406)		(298,953)		(277,630)

Operating (Loss)		(168,666)		(163,641)		(259,608)		(415,175)

License Fee		25,000		-		50,000		25,000

Other income		-		-		-		6,161

Interest (expense)		-		-		-		(3,371)

Net (Loss) Before Taxes		(143,666)		(163,641)		(209,608)		(387,385)

Deferred income tax benefit		4,300		4,300		12,900		12,900

Net (Loss)	$	(139,366)	$	(159,341)	$	(196,708)	$	(374,485)

Basic and diluted (loss) per share	$	(0.00)	$	(0.01)	$	(0.01)	$	(0.01)

Average number of common shares outstanding		29,410,000		28,890,500		29,194.500		27,061,000

Comments & Business Outlook

Thu, 27 Jun 2013 04:00:00 GMT

MT. KISCO, N.Y., June 27, 2013 (GLOBE NEWSWIRE) -- ImmuDyne, Inc. (OTCQB:IMMD) announced today that the Company is launching an investor awareness campaign beginning on July 9, 2013 and continuing throughout 2013. The Company will be implementing strategies and tactics designed to increase market awareness of ImmuDyne and its product portfolio, among strategic investors, institutions and analysts.

Mark McLaughlin, President and CEO, stated: "We are initiating an IR campaign as one of several steps we will be taking to foster company growth and increase shareholder awareness. During recent months significant progress has been made in identifying strategic partners and distribution channels for our product lines."

Karen Kingston, Chief Marketing Officer, stated: "I am pleased with the consumer and industry response we have received to our new product lines and branding, specifically Primed For Immunity™ (PFI™). We recently held our first PFI Experience Event with Kandy Magazine in Hollywood at the Drais on June 14, 2013. The PFI product, branding, and messaging were received with excitement and enthusiasm. Strong interest was expressed in establishing a strategic partnership from a potential distribution partner and in setting up a US and global network for the PFI product. We will be holding several other events in the Hollywood area this summer to increase demand of this breakthrough product. However, the big picture is the science behind our flagship beta 1/3,1/6 d-glucan product, PURACERE™. We will continue to educate consumers and strategic partners about the critical responsibilities of the immune system and how PURACERE's proprietary beta 1/3,1/6 d-glucan formulation naturally primes the immune system. Notably, the immune system is crucial in regulating the body's energy, weight, inflammation, skin, and even mood. As ImmuDyne continues to move forward with our business plan, PURACERE's applications across dozens of multi-billion dollar therapeutic and wellness markets will become more evident."

Research

Wed, 01 May 2013 04:00:00 GMT

Immudyne Inc (NBB:IMMD) ($0.29) shares have more than doubled since early April. Apparently, investors are excited about the direction that a new management team is taking the company. Specifically, management intends to market its healthcare products to the nutraceutical industry, as opposed to the biotech sector, which had been its prior focus. The initial focus will be in the anti-aging and skin care product categories. The company claims that its primary compound to be used in its products is the purest and most potent compound available on the market today.

In order to implement its marketing strategy, the company recently hired an executive who it claims was instrumental in helping large pharmaceutical companies, such as Phizer, successfully launch their new products. In a nutshell, the company feels that its new focus will significantly expand the application of its compound to a much larger market, thereby addressing its current challenge-not being able to efficiently expand its annual revenues past the current run-rate of around $700,00.

On April 18, 2013 management hosted a conference call that discussed in great detail the strides that the company intends to accomplish over the next fifteen months. Managemnent mentioned that its revenue run-rate should minimally top $10 million by the third quarter of 2014, which could translate into an EPS of $0.20. However, this guidance only takes into account one of several product categories that the company will serve. Although management goals seem quite aggressive, we will establish a small long-term position as we wait to see how the story unfolds.